Polio vaccine dose reductions could cut costs

A partial dose of the polio vaccine works just as well as a full one in providing a basic level of immunity against the disease, a new study shows. This could mean cheaper ways to ensure that the disease doesn't return to areas where it's been eliminated. The trial, funded by the World Health Organization and the Pan American Health Organization, indicates that vaccinating a child could cost only $1.20, down from $6. GlaxoSmithKline ($GSK), Sanofi ($SNY), Serum Institute of India and Statens Serum Institut all manufacture injected polio vaccines. Study | More

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.